USMJ Announces Success Of EVERx CBD Sports Nutrition Beverage Reboot At Arnold

    Author microcapwatchPosted on Categories CannabisTags , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

    Dallas, Texas, March 08, 2022 (GLOBE NEWSWIRE) — North American Cannabis Holdings, Inc. (OTC Pink: USMJ) today announced the success of its EVERx CBD Sports Nutrition Beverage reboot at the


    Arnold Sports Festival


    this past weekend.



    https://www.instagram.com/p/Caug0QqOZIu/

    Follow EVERx on Instagram:


    https://www.instagram.com/drinkeverx/

    “The new packaging and formula were both a hit,” said USMJ CEO Steven Rash.  “Following the Arnold EXPO, we now expect EVERx to be back on retail shelves very soon, adding to our current eCommerce sales on


    www.usmj.com


    . Look for retail announcements coming soon.”

    If you are interested in distributing EVERx, send us an email at


    [email protected]


    .

    To learn more about the new formula and to see the new packaging, visit:


    www.DRINKEVERx.com



    .

    To stay up to date on the latest EVERx developments, visit:

    Newsletter




    .

    USMJ acquired EVERx from its sister company, Puration, Inc. (OTC Pink: PURA) last year in exchange for a royalty agreement.

    EVERx is bottled by Alkame Holdings, Inc. (OTC Pink: ALKM). ALKM was instrumental in the development of the updated EVERx formula.

    Visit the company’s ecommerce site now and bookmark the site to watch for more coming announcements and updates:


    www.USMJ.com


    Contact:


    USMJ

    Steven Rash



    [email protected]



    +1 (800) 861-1350


    Disclaimer/Safe Harbor:

    This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company’s contracts, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.


    Attachments


    Primary Logo

    GlobeNewswire
    March 8, 2022 – 6:56 AM PST